0QNS Stock Overview
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kinarus Therapeutics Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.015 |
| 52 Week High | CHF0.04 |
| 52 Week Low | CHF0.015 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -38.40% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QNS | GB Airlines | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -0.5% |
| 1Y | n/a | -5.7% | 0.4% |
Return vs Industry: Insufficient data to determine how 0QNS performed against the UK Airlines industry.
Return vs Market: Insufficient data to determine how 0QNS performed against the UK Market.
Price Volatility
| 0QNS volatility | |
|---|---|
| 0QNS Average Weekly Movement | n/a |
| Airlines Industry Average Movement | 4.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QNS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0QNS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | https://www.kinarus.com |
Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.
Kinarus Therapeutics Holding AG Fundamentals Summary
| 0QNS fundamental statistics | |
|---|---|
| Market cap | CHF12.62m |
| Earnings (TTM) | CHF0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 0QNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QNS income statement (TTM) | |
|---|---|
| Revenue | CHF0 |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF0 |
| Other Expenses | CHF0 |
| Earnings | CHF0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0QNS perform over the long term?
See historical performance and comparison